公开(公告)号：US10604541B2

公开(公告)日：2020-03-31

申请号：US16318173

申请日：2017-07-21

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Peter Tai Wah Cheng ,  Wei Meng ,  Mark Liu ,  Bei Wang ,  Rulin Zhao

IPC: C07F9/40 ,  A61K31/675 ,  A61P3/00 ,  C07F9/6571 ,  A61P3/10

Abstract: A compound, enantiomer, prodrug, diastereomer, or salt is provided which is an activator of the enzyme glucokinase and thus is believed to be useful in as treating diabetes and related diseases, which compound has the structure (I). A method for treating diabetes and related disease employing the compound, enantiomer, prodrug, diastereomer, or salt is also provided.

公开(公告)号：US20190233449A1

公开(公告)日：2019-08-01

申请号：US16318173

申请日：2017-07-21

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Peter T.W. CHENG ,  Wei Meng ,  Mark Liu ,  Bei Wang ,  Rulin Zhao

IPC: C07F9/6571 ,  A61P3/10

CPC classification number: C07F9/657181 ,  A61P3/10 ,  C07B2200/13

Abstract: A compound, enantiomer, prodrug, diastereomer, or salt is provided which is an activator of the enzyme glucokinase and thus is believed to be useful in as treating diabetes and related diseases, which compound has the structure (I). A method for treating diabetes and related disease employing the compound, enantiomer, prodrug, diastereomer, or salt is also provided.